‫علي‬ ‫بناء‬ ‫المحول‬ ‫الطلب‬ ‫لدراس‬ ‫اقتصادية‬ ‫دراسة‬ ‫لعمل‬ ‫الدواء‬ ‫اقتصاديات‬ ‫وحدة‬ ‫إلي‬ ‫االدوية‬ ‫ونواقص‬ ‫الدعم‬ ‫إدراة‬ ‫من‬

 Introduction
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Globally, liver cancer is the 5th and 7th most common cancer in men and women, respectively. In many Egyptian regional registries, liver cancer is the first cancer in men and the second in women [1] . Risk factors for HCC vary among countries, but chronic infections with HBV and HCV are the most important precursors for HCC development on a global scale. In Egypt, HCV is the main risk factor for HCC where 71% of HCC cases are positive for anti-HCV antibodies [2] .
Local ablative procedures, such as percutaneous ethanol injection (PEI), radiofrequency ablation (RFA) or laser-induced thermotherapy (LITT), are potentially curative treatment methods that can be employed with a limited form of the disease; diffusely infiltrating or multifocal tumors, which are often present at the initial diagnosis, are not suitable for these treatment methods. Seventy per cent of patients are diagnosed at an advanced stage and can no longer benefit from curative treatment (surgical resection, liver transplantation, percutaneous ablation) [3] .
Transarterial chemoembolization (TACE) is the treatment recommended in patients with an unresectable, non-metastatic HCC who are in a good general condition with preserved hepatic function (intermediate stage B of the BCLC classification). TACE relies on both local provision of the anticancer agent and on the dual arterial and venous supply to the liver making it possible to temporarily interrupt arterial flow without inducing ischemic necrosis of the organ. Even though TACE has been practiced throughout the world for many years, the technique is still very heterogeneous, and depends on the centers and radiologists in charge of the procedure for the choice of anticancer agents, the doses, the vectors, the embolization agents, the perfusion procedures and the frequency of the courses [4] Since 2006, new medical devices, drug-eluting beads (DEB), have been used as the vector for anticancer agents for TACE of HCC. These expensive devices have the twin advantages of reducing the systemic release of the anticancer agent by releasing it in a controlled way on contact with the tumor and of embolizing the vessels supplying the hyper vascularised nodules. These two advantages are still theoretical in as far as the only randomized study published, which compared the efficacy and tolerance of TACE with doxorubicin-eluting beads with conventional TACE using lipiodol as the vector, did not demonstrate any significant difference in terms of efficacy at 6 months between the two techniques [5] No discounting was conducted.
Discounting outcomes
No discounting was conducted.
Sensitivity analysis-parameters and range
Critical component(s) in the calculation is varied through a relevant range or from worst case to best case.
Sensitivity analysis-methods
One-way sensitivity analysis is performed.
Presenting results
cTACE strategy is cost-effective intervention compared to DEB TACE in patients with hepatocellular carcinoma.
Incremental analysis yes Total costs vs. effectiveness (cost/effectiveness ratio) yes
Portability of results (Generalizability)
The generalizability and extent to which the clinical efficacy data and the economic data are representative is identified and discussed.
 Committee Discussion
It is important to identify the most cost-effective treatment in patients with hepatocellular carcinoma from a range of alternatives. To support reimbursement decision-making in Egypt, Decision analysis is a quantitative method for synthesizing data from numerous sources for the evaluation of treatment alternatives and was developed to determine the cost-effectiveness of the cTACE strategy, as compared to DEB TACE. This decision analytical model was constructed to assess the costs and consequences associated with cTACE compared with DEB TACE. The clinical parameters were derived from a retrospective comparison of therapy-associated complications on 44 patients with unresectable HCC and Child-Pugh A Cirrhosis. The evaluation of the therapy in this study was 8.1 months on average (SD±6.6).The results showed that DEB-TACE mean survival was significantly prolonged with 651±76 days vs. 414±43 days for cTACE with Lipiodol [6] (p=0.01) associated with a similar safety profile. The main limitation of the evidence is its retrospective character and the limited number of patients. It is likely that the framework conditions differed so that, for example, technical progress and increasing operator experience led to more frequent achievement of super selective catheter positioning, which might have favorably influenced the results in the DEB-TACE group. The total survival days of cTACE strategy was estimated to be 414 days whereas that of DEB TACE strategy was estimated to be 651 days. The total costs for cTACE strategy and DEB TACE strategy were EGP 420,529 and EGP 1,351,105 respectively. Thus the incremental cost effectiveness ratio (ICER) for cTACE versus DEB TACE is EGP 3,926 per one day survival gained.
As in all modeling exercises, several assumptions were made in this study leading to uncertainties in the results. In this analysis, we explicitly accounted for these uncertainties by assigning confidence intervals and plausible ranges of the survival days, tumor response, and drug costs based on published sources. To assess the influences of other model structures and assumptions on the cost-effectiveness estimates, one-way sensitivity analyses of various parameters were performed. The Deterministic sensitivity analysis demonstrated that survival associated by DEB TACE strategy and DEB-TACE operation costs have the greatest effect on the results. These various sensitivity analyses did not result in qualitatively different results, and the model proved to be rather robust.
 Conclusion
Results from this study suggest that employing a cTACE strategy is cost-effective intervention compared to DEB TACE in patients with hepatocellular carcinoma based on the willingness to pay threshold stated by world health organization (3xGDP/capita) for low and middle income countries. These findings will help inform health care decisions regarding the allocation of health care system resources to improve the health of the Egyptian population.
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